DB
DNLI icon

Dmitry Balyasny’s Denali Therapeutics DNLI Stock Holding History

Dmitry Balyasny’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
+432,800
New +$8.89M 0.01% 1009
2022
Q4 		– Sell
-25,000
Closed -$767K – 2874
2022
Q3 		$767K Buy
+25,000
New +$813K ﹤0.01% 1898

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's DNLI Position: Q2 2026 in Review

Dmitry Balyasny sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 195,108 shares — an estimated $4.01M sold.

Dmitry Balyasny first reported a position in DNLI in Q2 2019 and held it in 16 quarters. The position peaked at $8.48M in Q4 2024. 290 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Dmitry Balyasny reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 195,108 Denali Therapeutics shares in Q2 2026, an estimated $4.01M.
  • Dmitry Balyasny first reported a position in Denali Therapeutics in Q2 2019 and held it in 16 quarters.
  • Dmitry Balyasny's Denali Therapeutics position peaked at $8.48M in Q4 2024.
  • 290 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.